News updates
New computational platform predicts side effects
SeaChange recently reported a joint study in Nature with UC San Francisco and the Novartis Institutes for BioMedical Research that demonstrates the fully-automated application of a core technology to predict the side effect liabilities of drugs and preclinical compounds on an unprecedented scale. The platform's predictions were tested experimentally in 694 prospective lab assays and also against 348 proprietary data-points, yielding a success rate over twenty times higher than existing broad-scale computational approaches.
Companies or investors interested in learning more about SeaChange and our ability to find new uses for existing drugs and their side effects may contact science+seachangepharma*com.